Health ❯ Healthcare

Cancer Treatment

Immunotherapy Chemotherapy Targeted Therapy Radiation Therapy Combination Therapy Patient Care Oncology Surgery Therapeutic Strategies Breast Cancer Clinical Trials Radiotherapy Therapeutics Precision Medicine Prostate Cancer Therapies Survival Rates Surgical Oncology Therapeutic Approaches Drug Development Personalized Medicine Hormone Therapy Drug Therapy Therapeutic Targets Bladder Cancer Patient Support Targeted Therapies Clinical Research Remission Drug Resistance Innovative Therapies Proton Therapy Public Figures Early Detection Support Systems Diagnosis Adjuvant Therapy Recovery Pediatric Oncology King Charles Lung Cancer Hospitals Biomarkers Cellular Therapies Monoclonal Antibodies Hormonal Therapy Immune Checkpoint Inhibitors Screening Programs Endocrine Therapy Neoadjuvant Therapy Pharmaceuticals Royal Health Patient Experience Diagnostic Imaging Side Effects Research Alternative Medicine CAR T-cell Therapy Side Effects Management Diagnostic Procedures Metastatic Cancer Metastasis Lymphoma Stem Cell Transplantation Financial Burden Cancer Immunotherapy Public Health Recovery Process Liver Cancer Blood Cancers Cell Therapy Tumor Biology Patient Experiences Hormone Receptor Positive Cancer AI in Healthcare Breast Cancer Treatment Tumor Removal Palliative Care King Charles III Oncology Services Therapeutic Resistance Cancer Care Facilities Skin Cancer Radioisotopes Gene Therapy Chemotherapy Alternatives Preventive Measures Prostate Cancer Treatment Pancreatic Cancer Checkpoint Inhibitors Radiation Oncology Tumors Non-Small Cell Lung Cancer Relapse Detection Gliomas Uveal Melanoma Screening Techniques Alternative Therapies Multiple Myeloma Colorectal Cancer

Spanish Team Eradicates Pancreatic Tumors in Mice With Triple-Drug Regimen, PNAS Study Finds

Human trials have not begun, with scientists framing the mouse results as a guide for future combination studies.

New CAR T Strategy Targets Tumor Macrophages, Triggers Antitumor Immunity in Mice

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

ImmunityBio Sets 30-Day FDA Submission After Positive Meeting on Anktiva Expansion

San Francisco Leaders Press Blue Shield Over Retired Firefighter’s Cancer Coverage

ImmunityBio Rallies as Anktiva Sales Surge 700% and Registrational Trial Passes 85% Enrollment

Epcoritamab Improves PFS but Not OS in Phase 3 DLBCL Trial

Low CTDNEP1 Tied to Poorer Outcomes in Pancreatic Cancer, Study Finds

Tecvayli Cuts Progression Risk 71% and Deaths 40% in Phase 3 Myeloma Trial

Study Finds Blood Test Predicts Tarlatamab Benefit in Small Cell Lung Cancer

Pooled Data Tie Early AE Management to Greater Zolbetuximab Benefit in Gastric/GEJ Cancer

Splice-Switching ASO Collapses Oncogenic Circuit in Pancreatic Cancer Models

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

Harvard Study Finds Bias in Cancer Pathology AI and Unveils Training Fix Cutting Gaps by 88%

T Cell Receptor Switches From Closed to Open in Native Membrane, Rewriting Activation Model

Study Finds CBD–THC Combination Kills Ovarian Cancer Cells in Lab

Study Finds No Added Breast Cancer Risk From Menopausal Hormone Therapy in BRCA Carriers

Final Phase I Data Show Preventive TNBC Vaccine Is Safe and Induces Immune Responses in Most Participants

EMA Panel Backs Conditional EU Approval for Anktiva in BCG-Unresponsive Bladder Cancer